Europe to be Way Ahead in the Cognitive Impairment Disorders Treatment market between 2020 and 2030

Cognitive disorder implies to any type of disease, disorder or condition that harms the cognitive functioning of the person which results in improper functioning of the brain. Cognitive disorders involve memory problems and causes impairment in the functioning of brain. The major cognitive impairment disorders are delirium, dementia and amnestic disorder. Cognitive impairment varies from mild to severe. With mild cognitive impairment, patients experience mild symptoms but as the cognitive impairment becomes severe, patients started losing its thinking ability and as a result leads to complete memory loss. Alzheimer’s disease and other dementias with respect to conditions such as stroke, developmental disabilities and traumatic brain injury can lead to cognitive impairment. According to Center for Disease Control and Prevention report statistics, more than 16 million people in the United States are living with cognitive impairment. Cognitive impairment mostly affects people of age 65 years or older.

The global cognitive impairment disorders treatment market will contribute substantial revenue generation in the market owing to rising burden of cognitive impairment, growing number of aging population and increasing economic burden is likely to stimulate the growth of cognitive impairment disorders treatment market. Moreover, increase in brain injuries, chronic diseases such as Parkinson’s disease, diabetes and stroke may drive the cognitive impairment disorders treatment market. Currently, no cure has been developed to treat cognitive impairment caused by Alzheimer disease since date. Drugs that are approved for the treatment of Alzheimer’s disease has not shown benefit in treating cognitive impairment and thus it may hinder the growth of cognitive impairment disorders treatment market.

To remain ‘ahead’ of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/27751

The global cognitive impairment disorders treatment market is segmented on the basis of drug class, therapies type and end user.

• Cognitive Impairment Disorders Treatment Market Segmentation by Drug Class
  • Antiepileptic Drugs Cognitive Impairment Disorders Treatment
  • Antipsychotics Drugs Cognitive Impairment Disorders Treatment
• Cognitive Impairment Disorders Treatment Market Segmentation by Therapies Type
  • Symptomatic therapies Cognitive Impairment Disorders Treatment
    • Cholinesterase inhibitors Cognitive Impairment Disorders Treatment
    • Nootropic medications Cognitive Impairment Disorders Treatment
    • Ginkgo biloba Cognitive Impairment Disorders Treatment
    • Memory stimulants Cognitive Impairment Disorders Treatment
  • Preventive therapies Cognitive Impairment Disorders Treatment
    • Anti-oxidants
    • Omega fatty acids
    • Homocysteine
    • Cholinesterase inhibitors
    • Estrogen
    • Anti-inflammatory agents
    • Anti-amyloid therapies
    • Statins
    • Therapy for vascular risk factors
  • Cognitive Impairment Disorders Treatment Market Segmentation by End User
    • Hospital Pharmacies
    • Specialty Clinics
    • Retail Pharmacies
    • Drug Stores
    • Mail Order Pharmacies
    • Ambulatory Surgical Centers

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/27751

Geographically, cognitive impairment disorders treatment market is categorized into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to contribute substantial revenue in cognitive impairment disorders treatment market due to rising burden of cognitive impairment, high healthcare expenditure and availability of drugs which as a result increases the growth of cognitive impairment disorders treatment market. Similarly Europe intend to have increasing growth in cognitive impairment disorders treatment market owing to advancement in technology and also growing incidences of cognitive impairment that leads to growth of cognitive impairment disorders treatment market. Asia Pacific seems to have potential growth in cognitive impairment disorders treatment market due to high demand of treatment medication and rising economy which as a result leads to the growth of cognitive impairment disorders treatment market. Japan also contribute significant growth in cognitive impairment disorders treatment market due to growing aging population, increasing government initiatives in the region propel the growth of cognitive impairment disorders treatment market. Middle East and Africa have less contribution towards the growth of cognitive impairment disorders treatment market due to poor healthcare facilities, low economy and less availability of treatment options that may impact the growth of cognitive impairment disorders treatment market.

Some of the key players leading in cognitive impairment disorders treatment market are: Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Minerva Neurosciences, Intra-Cellular Therapies, Avineuro Pharmaceuticals, SyneuRx, Lundbeck, AB Science SA, AbbVie Inc, CHA Bio & Diostech Co Ltd, Echo Pharmaceuticals BV, Eisai Co Ltd, GlaxoSmithKline Plc, Grifols SA, Immungenetics AG, Otsuka Holdings Co Ltd, Merck & Co Inc, Kyowa Hakko Kirin Co Ltd and others.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/27751

About Us

Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws on its multi-disciplinary capabilities and high pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact Us:

Sourabh KJ

305 Broadway

7th Floor

New York City, NY 10007

United States

USA – Canada Toll-Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: https://www.persistencemarketresearch.com

Source MARKITWIRED